Following 1:1 propensity score matching, two well-balanced cohorts were established: patients with type 2 diabetes mellitus (T2DM) and inflammatory bowel disease (IBD) treated with GLP-1/GIP receptor agonists (semaglutide or tirzepatide) and those not treated with these agents. This evidence concerns the gene GCG and inflammatory bowel disease.